Johnson & Johnson Submits TECVAYLI EMA Application
Beerse, Belgium — March 10, 2026 Global healthcare company Johnson & Johnson has announced the submission of a Type...
Johnson & Johnson
Advertisement
Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy
HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...
Pasritamig Shows Strong Phase 1b Results in mCRPC
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
J&J Expands Stroke Care with CEREGLIDE System
IRVINE, Calif., February 26, 2026 Johnson & Johnson announced the U.S. launch of CEREGLIDE™ 42, CEREGLIDE™ 57 aspiration catheters,...
J&J Pasritamig Combo Shows Strong mCRPC Activity
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
Advertisements
J&J Files FDA Application for IMAAVY in wAIHA
February 24, 2026 – Spring House, Pennsylvania, USA Johnson & Johnson has announced the submission of a supplemental Biologics...
Johnson & Johnson Declares Q1 2026 Dividend, Signals Stability
NEW BRUNSWICK, NEW JERSEY | January 2, 2026 — Johnson & Johnson announced that its Board of Directors has...
J&J Acquires Halda to Advance Next-Gen Oral Cancer Drugs
NEW BRUNSWICK, N.J., Dec. 29, 2025 — Johnson & Johnson has completed the acquisition of Halda Therapeutics, bringing in...
INLEXZO Shows 74% One-Year Disease-Free Survival in High-Risk NMIBC
NEW BRUNSWICK, NJ — December 2025 — Johnson & Johnson announced new one-year results showing that its intravesical gemcitabine...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
Advertisement
